Reported Earlier, PolyPid Secures Up To $14M In Private Placement To Extend Cash Runway To Q2 2025
Portfolio Pulse from Benzinga Newsdesk
PolyPid secures up to $14M in a private placement, extending its cash runway to Q2 2025. The funding supports the ongoing SHIELD II Phase 3 trial of D-PLEX100, with top-line results expected in Q1 2025.
August 02, 2024 | 7:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PolyPid has secured up to $14M in a private placement, extending its cash runway to Q2 2025. This funding supports the SHIELD II Phase 3 trial of D-PLEX100, with top-line results expected in Q1 2025.
The secured funding extends PolyPid's cash runway, ensuring financial stability until Q2 2025. This is crucial for the ongoing SHIELD II Phase 3 trial of D-PLEX100, with significant milestones expected in Q1 2025. Positive trial results could further boost the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100